Literature DB >> 33413078

Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics.

Kristin L M Boylan1,2, Somaieh Afiuni-Zadeh1,3, Melissa A Geller4, Peter A Argenta4, Timothy J Griffin5, Amy P N Skubitz6,7,8.   

Abstract

BACKGROUND: The purpose of this study was to determine whether the residual fixative from a liquid-based Pap test or a swab of the cervix contained proteins that were also found in the primary tumor of a woman with high grade serous ovarian cancer. This study is the first step in determining the feasibility of using the liquid-based Pap test or a cervical swab for the detection of ovarian cancer protein biomarkers.
METHODS: Proteins were concentrated by acetone precipitation from the cell-free supernatant of the liquid-based Pap test fixative or eluted from the cervical swab. Protein was also extracted from the patient's tumor tissue. The protein samples were digested into peptides with trypsin, then the peptides were run on 2D-liquid chromatography mass spectrometry (2D-LCMS). The data was searched against a human protein database for the identification of peptides and proteins in each biospecimen. The proteins that were identified were classified for cellular localization and molecular function by bioinformatics integration.
RESULTS: We identified almost 5000 proteins total in the three matched biospecimens. More than 2000 proteins were expressed in each of the three biospecimens, including several known ovarian cancer biomarkers such as CA125, HE4, and mesothelin. By Scaffold analysis of the protein Gene Ontology categories and functional analysis using PANTHER, the proteins were classified by cellular localization and molecular function, demonstrating that the Pap test fluid and cervical swab proteins are similar to each other, and also to the tumor extract.
CONCLUSIONS: Our results suggest that Pap test fixatives and cervical swabs are a rich source of tumor-specific biomarkers for ovarian cancer, which could be developed as a test for ovarian cancer detection.

Entities:  

Keywords:  Biomarker; Mass spectrometry based proteomics; Ovarian cancer detection; Pap test

Year:  2021        PMID: 33413078      PMCID: PMC7792339          DOI: 10.1186/s12014-020-09309-3

Source DB:  PubMed          Journal:  Clin Proteomics        ISSN: 1542-6416            Impact factor:   3.988


  53 in total

1.  Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection.

Authors:  Georgina D Barnabas; Keren Bahar-Shany; Stav Sapoznik; Limor Helpman; Yfat Kadan; Mario Beiner; Omer Weitzner; Nissim Arbib; Jacob Korach; Tamar Perri; Guy Katz; Anna Blecher; Benny Brandt; Eitan Friedman; David Stockheim; Ariella Jakobson-Setton; Ram Eitan; Shunit Armon; Hadar Brand; Oranit Zadok; Sarit Aviel-Ronen; Michal Harel; Tamar Geiger; Keren Levanon
Journal:  Mol Cell Proteomics       Date:  2019-02-13       Impact factor: 5.911

2.  Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.

Authors:  Amy P N Skubitz; Kristin L M Boylan; Kate Geschwind; Qing Cao; Timothy K Starr; Melissa A Geller; Joseph Celestino; Robert C Bast; Karen H Lu; Joseph S Koopmeiners
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-01

3.  Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.

Authors:  Akira Kurosaki; Kosei Hasegawa; Tomomi Kato; Kenji Abe; Tatsuya Hanaoka; Akiko Miyara; Daniel J O'Shannessy; Elizabeth B Somers; Masanori Yasuda; Tetsuo Sekino; Keiichi Fujiwara
Journal:  Int J Cancer       Date:  2015-12-15       Impact factor: 7.396

4.  Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.

Authors:  Andreas Scorilas; Carla A Borgoño; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

Review 5.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

Authors:  Vladimir Nossov; Malaika Amneus; Feng Su; Jennifer Lang; Jo Marie Tran Janco; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Am J Obstet Gynecol       Date:  2008-05-12       Impact factor: 8.661

6.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

7.  Case report: detection of an advanced ovarian malignancy by cervical cytology.

Authors:  Deborah A Simon; Elizabeth Dimitrievich
Journal:  S D J Med       Date:  2003-10

8.  Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay.

Authors:  Carl Kapadia; Albert Chang; Georgia Sotiropoulou; George M Yousef; Linda Grass; Antoninus Soosaipillai; Xuekun Xing; David H C Howarth; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

9.  A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue.

Authors:  Hanne Haslene-Hox; Eystein Oveland; Kaja C Berg; Odd Kolmannskog; Kathrine Woie; Helga B Salvesen; Olav Tenstad; Helge Wiig
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

10.  Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Authors:  Christopher R Smith; Ihor Batruch; Josep Miquel Bauça; Hari Kosanam; Julia Ridley; Marcus Q Bernardini; Felix Leung; Eleftherios P Diamandis; Vathany Kulasingam
Journal:  Clin Proteomics       Date:  2014-06-02       Impact factor: 3.988

View more
  2 in total

Review 1.  Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.

Authors:  Shuvolina Mukherjee; Karin Sundfeldt; Carl A K Borrebaeck; Magnus E Jakobsson
Journal:  Proteomes       Date:  2021-05-25

Review 2.  Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.

Authors:  Joohyun Ryu; Stefani N Thomas
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.